血浆碱性成纤维细胞生长因子预测TACE治疗肝细胞癌的疗效

Forecasting therapeutic effect of TACE for hepatocellular carcinoma with plasma basic fibroblast growth factor

目的探讨血浆碱性成纤维细胞生长因子(bFGF)在肝细胞癌(HCC)患者TACE术后的变化,评价这种趋势与疗效的关系。方法对49例HCC行TACE,于术前及术后4周进行血浆bFGF、肝功能及CT检查。将术后4周血浆bFGF下降≥TACE术前bFGF的20%者纳入下降组,否则纳入未下降组。将TACE术后4周CT示肿瘤坏死区域面积≥肿瘤总面积的50%定义为肿瘤缓解。结果术前肿瘤直径≥5cm或合并乙型肝炎者bFGF较高。术后4周血浆bFGF下降组共16例,其肿瘤缓解率高于未下降组(P<0.05)。结论 HCC患者的血浆bFGF可能是预测TACE疗效的指标之一。TACE术后血浆bFGF下降的HCC患者更易发生肿瘤缓解,且其生存期明显延长。

Objective To explore the changes of plasma basic fibroblast growth factor（bFGF） in patients with hepatocellular carcinoma（HCC） after TACE,and to evaluate the association of these changes with therapeutic effect of TACE.Methods Forty-nine patients with HCC were treated with TACE.Measurement of plasma bFGF,liver function tests and CT scan were performed before and 4 weeks after TACE.Taking plasma bFGF decreased at least 20% in 4 weeks after TACE compared to the preoperative level as the standard,the patients were divided into decline group and non-decline group.Tumor remission was defined as tumor necrosis area accounting for at least 50% of the total tumor area through CT scan analysis 4 weeks after TACE.Results The bFGF levels in patients with tumor ≥5 cm or with hepatitis B were higher than that in patients with tumor 〈5 cm.There were 16 patients in decline group.Compared to non-decline group,the decline group had significantly higher tumor response rate（P〈0.05）.Conclusion Plasma bFGF may be used as a predictor for the efficacy of TACE in patients with HCC.Patients with HCC who have decline in plasma bFGF are more susceptible to tumor remission and have prolonged survival time.